title: Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.
abstract: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) has become a routine imaging modality for many malignancies and its use is currently increasing. In the present review article, we will summarize the evidence for FDG-PET/CT use in digestive cancers (excluding neuroendocrine tumours), and review the existing recommendations. While PET/CT is nowadays considered to be an important tool in the initial workup of oesophageal and anal cancers, new data are emerging regarding its use in assessing therapeutic efficacy, radiotherapy treatment planning, and detection of recurrence in case of isolated tumour marker elevation. Moreover, PET/CT may help decision making by detecting distant metastatic sites especially in potentially resectable metastatic colorectal cancer and, to a lesser extent, in localized gastric and pancreatic cancers. Finally, incidental focal colonic FDG uptakes require exploration by colonoscopy, as they are often associated with premalignant or malignant lesions.
authors.affiliation: Institut Curie, René Huguenin Hospital, Department of Nuclear Medicine, Saint-Cloud, France; Department of Nuclear Medicine, Centre Oscar Lambret, Lille, France. Electronic address: m-gauthe@o-lambret.fr.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Gauthé
authors.affiliation: Institut Curie, René Huguenin Hospital, Department of Radiation Therapy, Saint-Cloud, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Richard-Molard
authors.affiliation: Institut Curie, Department of Medical Oncology, Paris, France.
authors.forename: Wulfran
authors.initials: W
authors.lastname: Cacheux
authors.affiliation: Department of Gastroenterology, Rouen University Hospital, France; University of Rouen, Rouen, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Michel
authors.affiliation: Department of Gastroenterology, Dijon University Hospital, University of Burgundy, INSERM U866, Dijon, France.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Jouve
authors.affiliation: Institut Curie, René Huguenin Hospital, Department of Medical Oncology, Saint-Cloud, France; University of Versailles Saint Quentin, Faculty of Health Sciences, Montigny-Le-Bretonneux, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mitry
authors.affiliation: Institut Curie, René Huguenin Hospital, Department of Nuclear Medicine, Saint-Cloud, France; University of Versailles Saint Quentin, Faculty of Health Sciences, Montigny-Le-Bretonneux, France.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Alberini
authors.affiliation: Institut Curie, René Huguenin Hospital, Department of Medical Oncology, Saint-Cloud, France; University of Versailles Saint Quentin, Faculty of Health Sciences, Montigny-Le-Bretonneux, France.
authors.forename: Astrid
authors.initials: A
authors.lastname: Lièvre
mesh_terms: D004067:Digestive System Neoplasms / Q000175:diagnosis*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D064847:Multimodal Imaging; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D018358:Neuroendocrine Tumors / Q000175:diagnosis; D010347:Patient Care Planning; D049268:Positron-Emission Tomography; D017410:Practice Guidelines as Topic; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Anal canal cancer; Colorectal cancer; FDG-PET/CT; Oesophageal cancer; Pancreatic cancer